Key Highlights of Rafael Holdings Second Quarter Fiscal 2025
The anticipated merger with Cyclo Therapeutics is expected to finalize soon, pending necessary shareholder approvals.
Post-merger, Rafael Holdings will concentrate efforts on Cyclo’s primary clinical initiative, Trappsol Cyclo™.
Today, Rafael Holdings, Inc. (NYSE: RFL) reported its financial results for the second quarter and the first half of fiscal year 2025, which concluded on January 31, 2025. This period reflects significant strategic movements, particularly surrounding the merger with Cyclo Therapeutics (Nasdaq: CYTH).
Bill Conkling, CEO of Rafael Holdings, expressed optimism about the forthcoming shareholder vote regarding the merger with Cyclo Therapies and mentioned, "We anticipate a swift completion of the merger process. Upon its conclusion, our strategic focus will shift towards Trappsol Cyclo™, which we believe is poised to make a substantial impact in treating Niemann-Pick Disease Type C1." This indicates the company’s commitment to its clinical assets and the potential benefits for patients.
Financial Performance Overview
As of the end of January, Rafael Holdings held $48.3 million in cash and cash equivalents. The financial figures from this quarter reflect a net loss attributable to the company of $4.6 million, translating to a loss of $0.19 per share. In contrast, the previous year’s quarter reported a net income of $6.0 million or $0.25 per fully diluted share. The decline was primarily driven by a combination of unrealized losses of $1.1 million on investments made in Cyclo equity prior to the potential merger alongside unrealized losses on convertible notes receivable.
Research and development costs increased to $0.9 million for the quarter, up from $0.6 million the previous year. This increase correlates with activities at Cornerstone and Day Three, which were consolidated into Rafael Holdings in fiscal 2024.
While general and administrative expenses remained flat at $2.6 million for both quarters compared, this consistency reflects the company’s emphasis on stabilizing operational costs during this financial period.
First Half Performance Insights
For the first six months concluding on January 31, 2025, the company experienced a net loss of $13.6 million, equating to a loss of $0.57 per share, contrasting with a net income of $2.4 million or $0.10 per share reported in the previous cycle. The significant decline again relates to unrealized losses tied to investments in Cyclo, amounting to a total of $4.9 million, alongside similar issues with convertible notes receivable.
During this six-month span, R&D expenditures totaled $2.3 million, an upward shift from the previous year’s $1.1 million, again aligned with the activities at Cornerstone and Day Three. General and administrative expenses increased slightly to $5.1 million compared to the prior year’s $4.6 million.
About Rafael Holdings, Inc.
Rafael Holdings operates as a holding enterprise with stakes in various clinical and early-stage pharmaceutical enterprises. In addition to the pending merger with Cyclo Therapeutics, the company’s core focus includes developing Trappsol Cyclo™, which is actively undergoing clinical trials, particularly as a Phase 3 candidate for Niemann-Pick Disease Type C1. Rafael Holdings also maintains significant equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals Inc., Rafael Medical Devices, LLC, and Day Three Labs, Inc., demonstrating a commitment to diversifying its investment portfolio while targeting unmet medical needs. Following the merger's finalization with Cyclo, the primary focus will be on advancing Trappsol Cyclo™ as a lead clinical program.
Frequently Asked Questions
What is Rafael Holdings, Inc.'s recent financial standing?
As of January 31, 2025, Rafael Holdings reported $48.3 million in cash and equivalents alongside recorded losses attributable to shareholders.
What major strategic move is Rafael Holdings undertaking?
The company is currently finalizing its merger with Cyclo Therapeutics, focusing on advancing Trappsol Cyclo™ as its core clinical asset.
What are the anticipated results from Rafael's clinical programs?
Rafael Holdings expects to significantly impact patients suffering from Niemann-Pick Disease Type C1 with its clinical program.
How have recent investments influenced Rafael Holdings' performance?
Unrealized losses from investments in Cyclo Therapeutics have impacted Rafael’s financial performance, contributing to reported losses.
What future initiatives can investors expect from Rafael Holdings?
Post-merger, Rafael intends to emphasize its developmental focus on the medical efficacy of Trappsol Cyclo™ to address significant healthcare needs.
